Haemonetics 

$76.91
18
-$1.29-1.65% Monday 20:00

統計

當日最高
78.43
當日最低
75.93
52週高點
87.32
52週低點
47.32
成交量
701,588
平均成交量
-
市值
3.57B
本益比
37.52
股息殖利率
-
股息
-

即將到來

財報

11Aug預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
1.01
1.11
1.21
1.31
預期EPS
1.086299
實際EPS
不適用

財務

12.32%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.72B營收
335.36M淨利

分析師評級

79.00平均目標價
最高預估為 89.00。
來自過去6個月內的 6 則評分。這不是投資建議。
買入
67%
持有
33%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 HAE 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Show more...
執行長
Mr. Christopher A. Simon
員工
3657
國家
美國
ISIN
US4050241003

上市

0 Comments

分享你的想法

FAQ

Haemonetics 今天的股價是多少?
HAE 目前價格為 $76.91 USD,過去 24 小時下跌了 -1.65%。在圖表上更密切關注 Haemonetics 股票的表現。
Haemonetics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Haemonetics 的股票以代號 HAE 進行交易。
Haemonetics 的股價在上漲嗎?
HAE 股票較上週下跌 -2.29%,本月上漲 +36.63%,過去一年 Haemonetics 上漲 +9.93%。
Haemonetics 的市值是多少?
今天 Haemonetics 的市值為 3.57B
Haemonetics 下一次財報日期是什麼時候?
Haemonetics 將於 August 11, 2026 公布下一次財報。
Haemonetics 上一季度的財報如何?
HAE 上一季度的財報為每股 1.29 USD,預估為 1.27 USD,帶來 +1.36% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Haemonetics 去年的營收是多少?
Haemonetics 去年的營收為 2.72BUSD。
Haemonetics 去年的淨利是多少?
HAE 去年的淨收益為 335.36MUSD。
Haemonetics 有多少名員工?
截至 June 16, 2026,公司共有 3,657 名員工。
Haemonetics 位於哪個產業?
Haemonetics從事於Health & Wellness產業。
Haemonetics 何時完成拆股?
Haemonetics 上次拆股發生於 December 03, 2012,比例為 2:1。
Haemonetics 的總部在哪裡?
Haemonetics 的總部位於 美國 的 Boston。